ABSTRACT
INTRODUCTION
Childhood cancer survivors (CCSs) are at increased risk for long-term adverse health outcomes, including subsequent malignant neoplasms (SMNs). [1] [2] [3] [4] [5] Research among CCSs has shown a clear role of radiotherapy, with established dose-effect relationships for breast cancer, 6, 7 thyroid cancer, 8, 9 colorectal cancer, 10 sarcoma, [11] [12] [13] [14] CNS tumors, 15, 16 and basal cell skin cancer. 17 For chemotherapy, an increased risk of acute myeloid leukemia within 10 years of childhood cancer treatment has been well established for alkylating agents, epipodophyllotoxins, and anthracyclines. 18, 19 The role of chemotherapy in the etiology of solid cancers is less clear. Alkylating agents and anthracyclines were linked to increased risk of subsequent sarcoma. 11, 14, 20, 21 In addition, a recent Childhood Cancer Survivor Study among nonirradiated CCSs showed dose-dependent increases in breast cancer risk for these two classes of agents, particularly after childhood sarcoma and leukemia. 22, 23 Not much is known, however, about the effects of specific chemotherapy agents on breast cancer and sarcoma risk. To examine the role of specific chemotherapeutic agents, we evaluated the long-term risk of SMNs in the Dutch Childhood Cancer Oncology GroupLong-Term Effects after Childhood Cancer (DCOG LATER) cohort of 5-year CCSs.
METHODS
The DCOG LATER cohort includes 5-year CCSs treated before the age of 18 years in one of 
Data Collection
Details on prior cancer diagnosis and treatment of primary tumor and all recurrences were collected by trained data managers. Chemotherapy details included start and end dates, drug names, and given cumulative doses. For radiotherapy, details on prescribed dose, field, and boost/surdosage were recorded. In addition, names of other drugs and details on hematopoietic cell transplantation (HCT) were recorded. In case of missing chemotherapy doses when we knew the agent was given, we imputed mean doses of the agents administered to survivors within the same treatment protocol or to survivors from the same 27 SMNs until January 1, 2013, were identified as follows: We linked our cohort to the population-based Netherlands Cancer Registry (NCR), with nationwide coverage since 1989, 25 and, for the pre-1989 era, to the nationwide network and registry of histo-and cytopathology in the Netherlands (PALGA [Dutch Pathology Registry]). 26 Furthermore, we reviewed hospital medical records. Discrepancies between SMN sources were resolved by review of pathology reports. SMNs excluded myelodysplastic syndrome and basal cell carcinoma of the skin (not systematically ascertained by the NCR). We did include ductal carcinomas in situ in multivariable models on female breast cancer risk.
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Statistical Analyses
Time at risk started 5 years after childhood cancer diagnosis and ended on the date of SMN diagnosis, date of death, date of emigration, date of loss to follow up, or end of study (January 1, 2013), whichever occurred first. SMNs diagnosed ≥ 5 years after childhood cancer diagnosis were included as the outcome of interest. For survivors with multiple SMNs, only the first SMN was counted in analyses of all SMNs, and follow-up ended at the diagnosis of the first SMN. In cancer site-specific analyses, survivors contributed time at risk until the diagnosis of interest occurred, irrespective of possible preceding cancers. Standardized incidence ratios (SIRs) were calculated as the ratio of observed and expected number of SMNs. Excess absolute risks (EARs) were calculated as observed minus expected number of SMNs per 10,000 person-years of follow-up. Age-, sex-, and calendar year-specific rates from the Eindhoven Cancer Registry until 1988 and the NCR from 1989 onward were used to calculate expected numbers. 25, 27 Cumulative incidences of SMNs were estimated in the presence of death as a competing risk. 28 Cumulative incidences of any SMN after 15 years were compared for childhood cancer diagnosis period with use of pairwise Pepe-Mori tests. 29 Expected cumulative incidence was derived from expected cancer incidence adjusted for overall mortality in the general population. The effects of potential risk factors for all solid cancers combined and for the two most frequent solid cancers (breast cancer and sarcoma) were analyzed by using multivariable Cox proportional hazards regression models, with attained age as the time scale because cancer incidence varies by age. 30 All variables with P < .1 in univariable analyses were tested in multivariable models, except for chemotherapy agents with fewer than five exposed cases for the outcome of interest (Supplementary Table 1 
RESULTS
The cohort included 6,165 5-year CCSs who contributed 103,949 person-years of followup. Leukemia (34%), lymphoma (16%), and CNS tumors (14%) were the most frequent childhood cancers ( Figure 1 ).
Treatment-Related Risk Factors
Risk factors for subsequent breast cancer (n = 49, including five ductal carcinomas in situ), sarcoma (n = 55), and all solid tumors combined (n = 230) were evaluated in multivariable Cox proportional hazard regression analyses ( Abbreviations: BCC, basal cell carcinoma; EAR, excess absolute risk per 10,000 person-years; Obs., observed; PY, person-year; SIR, standardized incidence ratio; SMN, subsequent malignant neoplasm. a Ductal carcinoma in situ (five women, one man) was excluded from all analyses in this Incidence of subsequent sarcoma (Supplementary Table 4 ) was increased in survivors who received cyclophosphamide, with HRs of 0.2 (95% CI, 0.0 to 0.9), 1.7 (95% CI, 0.7 to 4.2), and 3.1 (95% CI, 1.5 to 6.0) for ≤ 4800, 4801 to 9400, and > 9400 mg/m², respectively (P trend = .01). Ifosfamide was also associated with increased risk of subsequent sarcoma (any v none HR, 2.6; 95% CI, 1.3 to 5.2) without a clear dose effect (P trend = .24). Other risk factors were TBI (HR, 4.5; 95% CI, 1.5 to 13.4) and any radiotherapy other than TBI (HR, 2.7; 95% CI, 1.5 to 4.9). The separate evaluation of risk for bone sarcoma and soft tissue or other extraosseous sarcoma showed that cyclophosphamide was associated with an increased risk of subsequent bone sarcoma, with HRs of 2.6 (95% CI, 0.6 to 11.1) and 8.2 (95% CI, 3.1 to 21.5) for medium and high dose, respectively (no low-dose-exposed survivors; P trend = .007), but not with an increased risk of other sarcomas, with HRs of 0.3 (95% CI, 0.1 to 1.2), 1.4 (95% CI, 0.5 to 4.3), and 1.1 (95% CI, 0.3 to 3.6) for low, medium, and high dose, respectively (P trend = .58; data not shown). We then restricted the cohort to CCSs treated without radiotherapy and found that sarcoma risks associated with cyclophosphamide dose were lower, with HRs of 0.9 (95% CI, 0.1 to 7.0) and 1.3 (95% CI, 0.2 to 10.1) for median and high dose, respectively (P trend = .69; data not shown). A model with the CED showed a significant alkylating agent dose response (P trend = .003; Table 3 , sarcoma model 2).
For all subsequent solid cancers, treatment effects were observed for TBI (HR, 4.7; 95% CI:
2.7 to 8.4); any radiotherapy other than TBI (HR, 1.9; 95% CI, 1.4 to 2.6); and doxorubicin dose, with HRs of 0.8 (95% CI, 0.5 to 1.2), 1.8 (95% CI, 1.1 to 2.9), and 2.5 (95% CI, 1.6 to 3.9) for ≤ 270 mg/m²; 271 to 443 mg/m², and > 443 mg/m², respectively (P trend < .001). For ifosfamide, some evidence of increased risk was observed in the highest dose tertile, with dose-tertilespecific HRs of 1.8 (95% CI, 0.9 to 3.8), 1.4 (95% CI, 0.7 to 2.6), and 2.5 (95% CI, 1.2 to 5.0), respectively (P trend = .15). Additional sensitivity analyses are reported in Supplementary Table 5 .
We found no significant CED dose response (P trend = .09), but we did for the anthracyclines agents as a group (P trend = .006). Women whose childhood cancer treatment included anthracyclines ≥ 250 mg/m² had a significantly higher risk than those treated without anthracyclines (HR, 1.9;
95% CI, 1.3 to 2.7; Table 3 , solid cancer model 2).
Finally, mercaptopurine and methotrexate, mainly used in leukemia and non-Hodgkin lymphoma protocols, were associated with decreased risks of subsequent solid cancers and sarcoma, respectively. After additional adjustment by childhood cancer type, these findings disappeared (not shown).
We performed separate analyses for leukemia, CNS tumor, and sarcoma survivors (except Ewing sarcoma; n = 3,578) because combinations of these cancer types are specific for LFS, and many of these survivors (especially of sarcoma) were exposed to high-dose cyclophosphamide and/or doxorubicin (Supplementary Table 6 ). The doxorubicin dose-response trend for breast cancer was stronger (P difference = .008) among female survivors of potentially LFS-associated childhood cancers (P trend < .001) versus other CCSs (P trend = .94; Table 4 ). The cyclophosphamide dose-response trend for subsequent sarcoma was not materially different (P difference = .98). Abbreviations: CED, cyclophosphamide equivalent dose; HR, hazard ratio; TBI, total body irradiation.
* Test for trend in continuous dose variable among exposed survivors. † Eligible cases include five women with a ductal carcinoma in situ of the breast (one before a breast carcinoma) and one breast cancer 37 
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after a nonbreast subsequent malignant neoplasm (endometrial carcinoma treated without radiotherapy or chemotherapy 7 years before breast cancer). ‡ Categories were based on approximate tertiles among exposed patients with subsequent solid cancer. § Eligible cases were 21 survivors with a subsequent bone sarcoma and 34 with a subsequent soft tissue or other extraosseous sarcoma.
Two survivors had a sarcoma after a nonsarcoma subsequent malignant neoplasm (acute lymphoblastic leukemia treated with TBI and chemotherapy 2 years before sarcoma and squamous cell carcinoma of the tongue treated without radiotherapy or chemotherapy 3 months before sarcoma).
║Eligible patients include three with solid cancers after a nonsolid subsequent malignant neoplasm (acute lymphoblastic leukemia treated with TBI and chemotherapy 2 years before solid cancer, acute lymphoblastic leukemia treated with TBI and chemotherapy 2 years before solid cancer, and one Hodgkin lymphoma treated with mantle field radiotherapy and chemotherapy 22 years before solid cancer). NOTE. All factors in the models have been adjusted for simultaneously. Attained age was used as the time scale in all models. Numbers do not always add up to the total because of missing values.
Abbreviations: HR, hazard ratio; LFS, Li-Fraumeni syndrome; NE, not estimable; SMN, subsequent malignant neoplasm; TBI, total body irradiation.
* The LFS-associated childhood cancer subcohort includes 5-year survivors of childhood leukemia and CNS tumors as well as survivors of sarcoma, except for Ewing sarcoma (n = 3,587). For breast cancer, only women were included (n = 1,608). † Includes all other 5-year childhood cancer survivors (n = 2,578). For breast cancer, only women were included (n = 1,123 
DISCUSSION
This study in a well-characterized cohort of Dutch CCSs strongly suggests that chemotherapeutic agents can increase the risk of solid cancers independent of radiotherapy. Doxorubicin was associated with a dose-dependent increased risk of female breast cancer, whereas cyclophosphamide increased subsequent sarcoma risk in a dosedependent manner. These findings are based on > 6,000 5-year survivors, with a median follow-up of 20.7 years since primary diagnosis, detailed therapy information, and highly complete follow-up for SMNs.
Doxorubicin exposure was associated with female breast cancer in a dose-dependent manner, particularly for women who may have had LFS-associated childhood cancer types.
These findings independently validate and extend a recent Childhood Cancer Survivor Study report on a dose-dependent increased breast cancer risk with cumulative anthracycline exposure (relative SIRs, 2.6 and 3.8 for 1 to 249 and ≥ 250 mg/m², respectively; P trend = .004) in female CCSs treated without chest radiotherapy, which was stronger among survivors of leukemia and sarcoma. 22 The current findings of a stronger doxorubicin dose response among survivors of LFS-associated cancer types compared with other CCSs suggest gene-anthracycline interaction in the development of breast cancer, perhaps with the inclusion of LFS or LFS-like syndromes, as hypothesized by Henderson et al. 22 Future collaborative studies that include family history of cancer and/or TP53 status are needed to truly disentangle the role that childhood cancer type, treatment details, and genetic factors play in the development of subsequent female breast cancer. We observed no effects of epirubicin and idarubicin, with only one and zero breast cancers occurring among exposed women, respectively. For daunorubicin (seven cases of breast cancer), risk was only increased in the multivariable model for the subcohort of LFS-associated childhood cancers (HR, 3.8; 95% CI, 1.1 to 13.2). An association between anthracyclines and (breast) cancer risk was previously suggested by smaller follow-up studies, particularly for doxorubicin, [36] [37] [38] and is supported by studies in rodents. [39] [40] [41] [42] [43] [44] We observed an increased risk of sarcoma after high-dose doxorubicin treatments in univariable analyses, but not after multivariable adjustment that included cyclophosphamide. This observation seemingly contrasts an earlier report on anthracycline-related sarcoma risk, which only crudely adjusted for other chemotherapy and not specifically for alkylating agents. 21 In all, the current result of a dose-dependent increased risk of solid cancer, particularly breast cancer, irrespective of radiotherapy treatment suggests that anthracyclines play a role in the etiology of breast cancer and perhaps other solid cancers.
Alkylating agents have been associated with many different solid cancers among (childhood) cancer survivors. 9-11,14,45-52 However, only a few studies identified specific agents (eg, procarbazine for gastrointestinal cancer [45] [46] [47] [48] 51 and cyclophosphamide for bladder and 42 pancreatic cancer 45, 53, 54 ). We did not find an increased risk of solid cancer after procarbazine exposure on the basis of data from 17 patients with a GI cancer. Cyclophosphamide, however, showed a dose-response relation with subsequent sarcoma, particularly bone sarcoma, in accordance with previous SMN studies 11, 14, 45, 53, 54 and experimental data. 55, 56 Previous treatment with ifosfamide also resulted in increased risks of female breast cancer, sarcoma, and all solid cancers among CCSs. We interpret this finding with caution because the seemingly elevated overall risk was not paralleled by clear dose-response patterns or is supported by other epidemiologic studies on carcinogenicity of ifosfamide, although some evidence from animal studies exists. 57, 58 We chose to focus on agent-specific dose information because the various agents collated in chemotherapy agent categories on the basis of structure and/or anti-tumor mechanism may not necessarily have similar carcinogenic properties. Moreover, aggregate measures of chemotherapy exposures are based on acute hematologic toxicity 32 or late cardiac toxicity, 59 or they are cohort specific, which limits comparability across cohorts.
14,60
Although we observed significant associations between anthracycline dose and risk of breast cancer and all solid cancers, they were confined to doxorubicin. For sarcoma, we observed a significant dose response for the CED, but when we examined specific agents, only cyclophosphamide dose seemed to be associated with sarcoma. Radiotherapy was associated with solid cancer risk, with stronger effects for TBI than for other radiotherapy, which may be related to the large volume of the body treated in TBI, a high dose per fraction, or HCT-related immunologic alterations. The major strengths of this study are the large cohort size, detailed information on individual treatments, and availability of highly complete SMN follow-up by record linkage and medical information. A limitation of the study is that the number of events for most SMN sites were still fairly low as a results of the age distribution at end of follow-up.
In addition, as in other survivorship cohorts, correlations between patient and treatment factors, which reflects clinical reality, sometimes hampered the ability to disentangle effects in multivariable analysis. 22 Furthermore, we tested many variables in our models and performed various post hoc tests to validate the findings, so we cannot exclude the possibility that some of the findings are based on chance.
In conclusion, the results strongly suggest that CCSs who received treatment, including TBI, other radiotherapy, doxorubicin, or cyclophosphamide, are at the highest risk for 43 developing subsequent solid cancers. In addition, our observations indicate that genetic susceptibility may influence doxorubicin-associated breast cancer risk. The results of this study will inform future childhood cancer treatment protocols as well as SMN surveillance guidelines for former patients.
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SUPPLEMENTARY MATERIALS

Supplementary Methods
Radiotherapy exposure assessment
For every individual in the cohort who had radiotherapy for initial cancer and/or recurrences, we collected information on body compartment of the radiotherapy and prescribed dose per body compartment. Radiotherapy, excluding total body irradiation (TBI), was evaluated in the models as yes/no variables (any radiotherapy yes/no for sarcoma and for all solid cancer; chest radiotherapy yes/no for female breast cancer) and in prescribed dose categories if at least 10 exposed cases for the outcome of interest occurred (maximum dose to any body compartment for any solid cancer and sarcoma; maximum dose to the chest for breast cancer). Chest radiotherapy was defined as any field including the thoracic region, excluding spinal irradiation and TBI. TBI was evaluated separately from other radiotherapy.
Imputation missing chemotherapy doses
Of all survivors treated with chemotherapy, we did not know the exact dose in 17.8% of the administrations. For all those missing administrated dosages we knew which agent was
given, but the exact dose was missing. The number of survivors for whom chemotherapy doses were missing for all administrations was only 1%. In case of a missing administrated dose, we imputed this data. For survivors with a known treatment protocol, we imputed the mean dose of other survivors who had the same protocol (if at least 3 survivors had the same protocol). For survivors without a known protocol, we imputed the mean dose of all survivors with the same diagnosis group and diagnosis period (5-year period).
The degree of missingness varied strongly between agents. For example, for doxorubicin and cyclophosphamide, two commonly used agents of main interest, only 3% and 6% of the administrated doses were missing, respectively. We performed sensitivity analyses without the imputed doses (thus excluding survivors with a missing dose for one of the variables in the model) and this did not materially change our results. Abbreviations: EAR, excess absolute risk per 10,000 person-years; Obs., observed; SIR, standardized incidence ratio. NOTE. All factors in the models were adjusted for simultaneously. Attained age was used as the time scale in all models. Abbreviations: HR, hazard ratio; TBI, total body irradiation. * Adjusted for tertiles of radiotherapy dose. Tertile-specific HRs were 5.9 (95% CI, 0.8 to 46.4), 6.5 (95% CI, 0.8 to 54.8), and 7.9 (95% CI, 1.0 to 64.2) for ≤ 25 Gy, 26-45 Gy, and > 45 Gy, respectively. † Test for trend in continuous dose variable among exposed survivors. ‡ Categories were based on approximate tertiles among exposed survivors with subsequent solid cancer. NOTE. Percentages do not always add up to 100% because of missing data. Abbreviation: TBI, total body irradiation. * Treatment data include primary treatment and all recurrences; chemotherapy (yes/no), radiotherapy (yes/no), surgery (yes/no), and hematopoietic cell transplantation (yes/no) data were missing for 48, 41, 73, and 90 survivors, respectively. † High dose was defined according to the second or third tertile of exposure, (ie, a dose of >4800 mg/m² cyclophosphamide and a dose of >270 mg/m² doxorubicin).
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